Last reviewed · How we verify

CTX-4430 — Competitive Intelligence Brief

CTX-4430 (CTX-4430) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NADPH oxidase 2 inhibitor. Area: Immunology.

phase 2 NADPH oxidase 2 inhibitor NOX2 Immunology Small molecule Live · refreshed every 30 min

Target snapshot

CTX-4430 (CTX-4430) — Celtaxsys, Inc.. CTX-4430 is a small molecule inhibitor of the NADPH oxidase 2 (NOX2) enzyme.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CTX-4430 TARGET CTX-4430 Celtaxsys, Inc. phase 2 NADPH oxidase 2 inhibitor NOX2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NADPH oxidase 2 inhibitor class)

  1. Biohaven Pharmaceuticals, Inc. · 1 drug in this class
  2. Celtaxsys, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CTX-4430 — Competitive Intelligence Brief. https://druglandscape.com/ci/ctx-4430. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: